铁筷子多糖联合内分泌治疗晚期前列腺癌的疗效

doi:10.3969/j.issn.1671-7171.2022.07.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1153 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨铁筷子多糖联合内分泌治疗晚期前列腺癌的临床疗效及铁筷子多糖对前列腺癌细胞的抑制作用。【方法】回顾性分析两院收治的154例晚期前列腺癌患者的临床资料,根据治疗方法的不同将其分为对照组(内分泌治疗)和观察组(铁筷子多糖联合内分泌治疗),每组77例。比较两组患者治疗前后前列腺特异抗原(PSA)和游离前列腺特异抗原(F-PSA)水平,比较两组患者生活质量及国际前列腺癌症状量表(I-PSS)评分,比较不同剂量铁筷子多糖对DU145细胞周期的影响。【结果】治疗后, 两组患者PSA、F-PSA水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组患者QLQ-C30评分、I-PSS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。高剂量组G₀/G₁期细胞比例显著低于对照组、低剂量组,差异有统计学意义(P<0.05);高剂量组、低剂量组S期细胞比例显著高于对照组,低剂量组高于对照组(P<0.05)。观察组的并发症发生率低于对照组,差异有统计学意义(P<0.05)。【结论】铁筷子多糖联合内分泌治疗晚期前列腺癌临床疗效较好,且铁筷子多糖可较好抑制前列腺癌细胞。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：前列腺肿瘤/中西医结合疗法, 前列腺肿瘤/病理学, 铁筷子属/药物作用, 雄激素拮抗药/治疗应用

Abstract：【Objective】 To investigate the clinical efficacy of Helleborusthibetanus Franch polysaccharide (HFPS) combined with endocrine therapy for advanced prostate cancer and its inhibitory effect on prostate cancer cells. 【Methods】 The clinical data of 154 patients with advanced prostate cancer treated in our hospital were retrospectively analyzed. According to the different treatment methods, they were divided into control group (endocrine therapy) and observation group ( Helleborusthibetanus Franch combined with endocrine therapy), with 77 cases in each group. The levels of prostate-specific antigen (PSA) and free prostate-specific antigen (F-PSA) were compared between the two groups before and after treatment. The quality of life and international prostate cancer symptom scale (I-PSS) scores of the two groups were compared, and the effects of different doses of HFPS on DU145 cell cycle were compared. 【Results】After treatment, the levels of PSA and F-PSA in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05); The QLQ-C30 and I-PSS scores of the two groups were lower than those before treatment, and the observation group was lower than that of the control group, the difference was statistically significant (P<0.05). The proportion of G₀/G₁ cells in the high-dose group was significantly lower than that in the control group and low-dose group (P<0.05); The proportion of S-phase cells in the high-dose group and the low-dose group was significantly higher than that in the control group, and that in the low-dose group was higher than that in the control group (P<0.05). The incidence of complications in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Helleborusthibetanus Franch polysaccharide (HFPS)combined with endocrine therapy has a good clinical effect on advanced prostate cancer, and Helleborusthibetanus Franch polysaccharide can better inhibit prostate cancer cells.

Key words： Prostatic Neoplasms/ZJ Prostatic Neoplasms/PA Helleborus/DE Androgen Antagonists/ TU

收稿日期: 2022-05-14

中图分类号:

R737.25

基金资助:广州市中医药和中西医结合科技项目 (20192A010029)

通讯作者: **E-mail: bulesimon@sina.com

引用本文:

程璐, 曾昭昌, 刘远灵, 郑秋平, 万颂, 华伟, 周宇林, 江文聪, 杨盛帮, 习明. 铁筷子多糖联合内分泌治疗晚期前列腺癌的疗效[J]. 医学临床研究, 2022, 39(7): 995-998.
CHENG Lu, ZENG Zhao-chang, LIU Yuan-ling,et al. Clinical Study of Helleborusthibetanus Franch Polysaccharide (HFPS) Combined with Endocrine Therapy for Advanced Prostate Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 995-998.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.07.010 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I7/995

[1] LITWIN M S.The diagnosis and treatment of prostate cancer: a review[J].JAMA,2017,317(24):2532-2542.
[2] WANG G,DEPINHO R A. Genetics and biology of prostate cancer[J].Genes Dev,2018,32(17-18):1105-1140.
[3] 双卫兵,夏漫城. 前列腺癌根治术相关内分泌治疗[J].现代泌尿生殖肿瘤杂志,2018,10(3):189-191.
[4] BARTOLI G,RUFFINI CASTIGLIONE M. Female gametophyte and embryo development in Helleborus bocconei Ten. (Ranunculaceae)[J].Protoplasma,2017,254(1):491-504.
[5] 田航周. 试论陕产铁筷子的化学成分及药理作用[J].家庭医药,2018(11):377-378.
[6] 汪鑫,蔡凯,王梁,等. 前列腺癌骨转移的预测因素分析[J].中国医科大学学报,2018,47(11):1025-1028.
[7] 高强,张保,史玉强,等. 新辅助内分泌治疗后行腹腔镜下前列腺癌根治术治疗局部晚期前列腺癌的临床分析[J].现代泌尿生殖肿瘤杂志,2018,10(3):145-148.
[8] 江城,许春,刘焜,等. 戈舍瑞林联合比卡鲁胺对晚期前列腺癌患者疗效分析[J].肿瘤药学,2017,7(6):678-682.
[9] ISAACSSON VELHO P,ANTONARAKIS ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer[J].Expert Rev Clin Pharmacol,2018,11(5):475-486.
[10] 曹威,李娟,程伟,等.铁筷子提取物对肿瘤细胞增殖及COX-2mRNA表达的抑制作用[J].广西植物,2014,34(2):189-193.
[11] 彭新庆,阮贤球,韦广飞,等. 内分泌疗法、经尿道前列腺电切术及化疗联合治疗中晚期前列腺癌的临床分析[J].广西医科大学学报,2018,35(3):405-407.
[12] 李秀男,秦杰,张浚鹏,等. 比卡鲁胺联合戈舍瑞林不同给药方式治疗晚期前列腺癌的效果比较及对血清PSA、VEGF和miR-34a表达的影响[J].中国医药导报,2018,15(6):53-57.
[13] 张晓冬,贺利民,马磊,等. 戈舍瑞林联合比卡鲁胺间歇性与连续性治疗对晚期前列腺癌患者前列腺抗原及免疫功能的影响[J].现代肿瘤医学,2018,26(3):426-429.
[14] WARD A B,SINGH S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways[J].World J Surg Oncol,2018,16(1):108.
[15] 唐旭,赵卫红,宋琴琴,等. SOX10对前列腺癌细胞增殖及侵袭的影响[J].北京大学学报(医学版),2018,50(4):602-606.